Abstract
References
- 1-Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34(3):307-10.
- 2-Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm. 2014;2014:232167. doi: 10.1155/2014/232167. Epub 2014 May 6.
- 3- Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012 Jul;36(1):39-45.
- 4- Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath. 2014 Jul 24. (Epub ahead of print).
- 5- Zhou S, Nao J. Nesfatin-1: A biomarker and potential therapeutic target in neurological disorders. Neurochem Res. 2023. https://doi.org/10.1007/s11064-023-04037-0.
- 6. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443: 709-12.
- 7. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31: 543-7.
- 8. Kim J, Yang H. Nesfatin-1 as a new potent regulator in reproductive system. Dev Reprod 2012; 16: 253-64. 9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006; 6(10): 772–78.
- 10. Conde J, Scotece M, G´omez R.et al. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37( 6):413–420.
- 11. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie. 2012; 94(10):2180–2189. 12. Sood A. Obesity, adipokines, and lung disease. Journal of Applied Physiology. 2010;108(3):744–753.
- 13. Scotece M, Conde J, Vuolteenaho K, et al. Adipokines as drug targets in joint and bone disease. Drug Discovery Today. 2014;19(3): 241–258.
- 14. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y, A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun. 2012;418:676–681.
- 15. Çatlı G, Anık A, Küme T, Çalan ÖG, Dündar BN, Böber E, et al. Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J Endocrinol Invest. 2015; 38: 909-13.
- 16. Park MG, Ko KW, Oh MM, Bae JH, Kim JJ, Moon du G. Effects of smoking on plasma testosterone level and erectile function in rats. J Sex Med. 2012; 9: 472-81.
- 17. Ayada C, Toru Ü, Korkut Y . Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19 (1): 4-10. 7s.
- 18. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013; 14: 189-195.
- 19. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depotspecific adipokine with increased levels in obesity. Endocrinology. 2010; 151: 3169-80.
Abstract
Aim: Nesfatin-1 is a recently discovered adipocytokine that is believed to regulate food intake and is linked to body mass index. While its precise mechanism of action remains unclear, a deeper understanding of how nesfatin-1 interacts with metabolic diseases, inflammation, and insulin resistance could have significant implications for the treatment of a wide range of conditions, including cardiovascular disease.
Smoking is a complex issue with roots in social, cultural, and economic factors that can contribute to nicotine addiction. Additionally, nicotine's ability to stimulate the mind and promote feelings of relaxation can create a positive feedback loop that makes it difficult to quit. Unfortunately, there is limited research on the effects of smoking on Nesfatin-1 levels. However, one study found that women who smoke tend to have lower levels of Nesfatin-1. To build on this finding, the present study aims to further investigate nesfatin-1 levels in both smokers and non-smokers.
Methods: A total of 70 participants, smokers (n=35) and non-smokers (n=35), were included in the study. The participant's gender, age, height and weight, body mass index, and nesfatin-1 levels were measured and compared.
The SPSS 23.0 program was used to evaluate the data statistically. Data were evaluated with a t-test. The error level was taken as 0.05.
Result: Serum Nesfatin-1 levels were significantly higher in smokers (13.73± 3.11) than in non-smokers (8.63 ± 0.91) (t=-9.315, p<0.01). No significant difference was found between other parameters in the smoker and non-smoker groups.
Conclusion: Our study has shown that individuals who smoke display higher levels of Nesfatin-1 compared to non-smokers, indicating a correlation between smoking and Nesfatin-1. However, further investigation is required to understand the mechanism behind this increase. It is hoped that continued research will unveil the potential of Nesfatin-1 in treating human obesity.
Ethical Statement
Prior to conducting the research, appropriate permissions and ethical clearance were secured from the (No. 2019-03/02) was obtained from the Sivas Cumhuriyet University Faculty of Medicine Ethics Committee. In this manner, individuals provided informed consent before their participation.
References
- 1-Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34(3):307-10.
- 2-Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediators Inflamm. 2014;2014:232167. doi: 10.1155/2014/232167. Epub 2014 May 6.
- 3- Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012 Jul;36(1):39-45.
- 4- Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath. 2014 Jul 24. (Epub ahead of print).
- 5- Zhou S, Nao J. Nesfatin-1: A biomarker and potential therapeutic target in neurological disorders. Neurochem Res. 2023. https://doi.org/10.1007/s11064-023-04037-0.
- 6. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443: 709-12.
- 7. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015; 31: 543-7.
- 8. Kim J, Yang H. Nesfatin-1 as a new potent regulator in reproductive system. Dev Reprod 2012; 16: 253-64. 9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology. 2006; 6(10): 772–78.
- 10. Conde J, Scotece M, G´omez R.et al. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37( 6):413–420.
- 11. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie. 2012; 94(10):2180–2189. 12. Sood A. Obesity, adipokines, and lung disease. Journal of Applied Physiology. 2010;108(3):744–753.
- 13. Scotece M, Conde J, Vuolteenaho K, et al. Adipokines as drug targets in joint and bone disease. Drug Discovery Today. 2014;19(3): 241–258.
- 14. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y, A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun. 2012;418:676–681.
- 15. Çatlı G, Anık A, Küme T, Çalan ÖG, Dündar BN, Böber E, et al. Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J Endocrinol Invest. 2015; 38: 909-13.
- 16. Park MG, Ko KW, Oh MM, Bae JH, Kim JJ, Moon du G. Effects of smoking on plasma testosterone level and erectile function in rats. J Sex Med. 2012; 9: 472-81.
- 17. Ayada C, Toru Ü, Korkut Y . Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19 (1): 4-10. 7s.
- 18. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013; 14: 189-195.
- 19. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depotspecific adipokine with increased levels in obesity. Endocrinology. 2010; 151: 3169-80.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Services and Systems (Other) |
| Journal Section | Medical Science Research Articles |
| Authors | |
| Publication Date | December 31, 2023 |
| Submission Date | December 27, 2023 |
| Acceptance Date | December 28, 2023 |
| Published in Issue | Year 2023Volume: 45 Issue: 4 |
